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1. Introduction 
Overactive bladder (OAB) is a symptomatic complex affecting both men and women. The 
overall incidence is above 10% but may exceed 40% in the elderly population (Irwin et al., 
2006; Irwin et al., 2009; Sexton et al., 2009a). OAB is defined by the International Continence 
Society (ICS) as a clinical syndrome characterized by urinary urgency, with or without 
incontinence, usually with frequency and nocturia (Abrams et al., 2002, 2003; Hashim & 
Abrams, 2007). Urgency, which is a storage symptom defined as a sudden compelling desire 
to pass urine difficult to defer, is the hallmark symptom as it is the only one that must be 
present in order to establish the diagnosis of OAB (Abrams et al., 2002, 2003). Several co-
morbidities are very common among OAB patients, including depression, insomnia and 
fractures (Coyne et al., 2008; Sexton et al., 2009a; Sexton et al., 2009b). The economic costs of 
OAB, associated with medical consultations, therapy and diminished productivity at work, 
may reach billions of dollars (Irwin et al., 2009) and will certainly increase with the 
demographic shift of an ageing population. 
The true causes of urgency/OAB remain poorly understood. The difficulty in establishing 
animal models that accurately represent urgency/OAB still holds. It was originally thought 
that the origin of OAB could be ascribed to anomalies in the neuromuscular junction and 
myocites. More recent data indicate a strong involvement of bladder sensory mechanisms 
involving the urothelium and suburothelial afferent nerves. In addition, dysfunction of 
central nervous system centres that control the micturition reflex, including the 
Periaqueductal Gray (PAG) and pontine micturition centre, has been implicated in the 
genesis of OAB (Fowler et al., 2008; Drake et al., 2010; Fowler & Griffiths, 2010).  
No cure exists for OAB. Management is initiated by exclusion of confounding diseases and 
by the introduction of conservative measures, including limiting fluid intake, avoiding 
caffeinated, acidic and carbonated drinks, weight reduction, smoke avoidance and bladder 
training. If bothersome OAB symptoms persist, patients are initiated on antimuscarinic 
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therapy, the current mainstay for pharmacological management of OAB (Henderson & 
Drake, 2010; Athanasopoulos & Cruz, 2011). Nevertheless, despite significant improvement, 
antimuscarinics still produce important side-effects that may lead patients to discontinue 
treatment (Andersson, 2004; Andersson et al., 2009; Gulur & Drake, 2010). Moreover, 
antimuscarinics are contra-indicated for patients with narrow angle, may interfere with 
cognitive function and aggravate constipation (Gulur & Drake, 2010), all of which 
commonly occur in the typical OAB age group. More recently, the administration of 
vanilloids and botulinum toxin have been proposed as a possible treatment for OAB but 
these approaches should be taken with care as they are off-label procedures (Cruz & Dinis, 
2007; da Silva & Cruz, 2009).  
The key symptom in OAB, urgency, may often be confounded with urge to void. Urge is a 
normal bladder sensation, the intensity of which is proportional to the degree of bladder 
filling and allows the subject to fully control bladder function. Differentiation between urge 
and urgency may not always be an easy task for the caregiver or patients, particularly those 
who are cognitively impaired by age or disease (Michel & Chapple, 2009a, b). In addition, 
grading urgency is a difficult task to be accomplished by the clinician, even with the use of 
standardized questionnaires (Nixon et al., 2005; Starkman & Dmochowski, 2008). Currently, 
there is no objective test to diagnose OAB although several attempts have been made in 
order to overcome this. Here, we will review recent data proposing new biomarkers for a 
better characterization of OAB patients. The value of a biomarker in medicine is 
considerable and lies in its ability to identify the disease, back diagnostic and therapeutic 
decisions and establish a valuable prognosis to the condition. In addition, it will positively 
influence the outcome of the condition. In OAB, investigators have focused on bladder 
parameters (the presence of detrusor overactivity and the thickness of the bladder wall), 
serum proteins (the C reactive protein) and urinary elements (prostaglandins, cytokines and 
neurotrophins). 
2. Bladder criteria 
2.1 Detrusor overactivity 
Detrusor overactivity (DO) is the urodynamic observation of involuntary detrusor contractions 
during the filling phase of cystometry (Abrams et al., 2002).Thus, DO can only be detected by 
urodynamic assessment, an invasive and expensive test. It has been demonstrated that DO 
was present in approximately 45% of OAB-dry and 60% of OAB-wet patients (Hashim & 
Abrams, 2006). As the main symptoms of OAB may suggest the presence of DO, several 
attempts have been made in order to correlate urgency with DO. However, in a recent study it 
was shown that reports of urgency sensations during filling cystometry were as likely to occur 
before or after an episode of DO and approximately one third of the DO events recorded were 
not associated with urgency (Lowenstein et al., 2009). In addition, DO, may be found in 
healthy individuals (Heslington & Hilton, 1996; van Waalwijk van Doorn et al., 1997; Hashim 
& Abrams, 2006). In fact, in the study by Hashim and Abrams 36% of the OAB patients studied 
(1076) did not present DO and more than 30% of individuals without OAB had DO (Hashim & 
Abrams, 2006).  In addition, DO does not predict the response of patients to antimuscarinic 
treatment (Malone-Lee & Al-Buheissi, 2009). Hence, the combination of the discomfort felt by 
patients during an urodynamic evaluation with a low predictive value both for the diagnosis 
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and successful outcome of OAB treatment impedes the routine use of urodynamic assessment 
for the majority of OAB patients. In a recent study, investigators tried to identify the presence 
of involuntary detrusor contractions through near-infrared spectroscopy (NIRS), a non-
invasive method (Farag et al., 2011a; Farag et al., 2011b). NIRS is an imaging technique that can 
be used to monitor haemodynamic events. As the name indicates, it uses light in the near-
infrared area, which is able to penetrate the skin. It is absorbed by oxyhaemoglobin and 
deoxyhaemoglobin, the levels of which can reflect oxygen consumption. In those studies, 
investigators were able to demonstrate that detrusor contractions were accompanied by 
changes in those chromophores (Farag et al., 2011a; Farag et al., 2011b). The overall specificity 
of NIRS to detect DO was 86% when measuring oxyhaemoglobin, 80% for deoxyhaemoglobin 
and 72% for the sum of both chromophores. Despite obvious limitations, such as the inclusion 
of more men than women, results are interesting and deserve further investigation.  
2.2 Bladder wall thickness/Detrusor thickness (BWT/DT) 
In patients with bladder outlet obstruction, the thickness of the total bladder wall or simply 
the thickness of the detrusor layer was shown in several studies to be significantly increased 
in OAB patients when compared with healthy volunteers (Hakenberg et al., 2000; Oelke et 
al., 2006; Oelke et al., 2007). Hence, it was forwarded that BWT/DT could be influenced by 
the work overload of the bladder wall introduced by DO. Indeed, some authors have 
reported a trend of increasing DT associated with the severity of urgency as reported by 
Panayi and coworkers (Panayi et al., 2010). Khullar and co-workers analysed the total BWT 
via transvaginal ultrasound in a group of female patients with idiopathic DO (Khullar et al., 
1996). They found that 58.7% of all analysed subjects had a mean BWT greater than 5 mm, 
94% of which had DO. Only 1.6% of subjects had DO with a BWT of 3.5 mm or less. The 
authors proposed that the measurement of mean BWT by transvaginal ultrasound, with a 
cut-off of 5mm, is a suitable screening method (Khullar et al., 1996). In addition, by 
determining BWT also with transvaginal ultrasound, Kuhn and co-workers were able to 
differentiate between women suffering from stress urinary incontinence or bladder outlet 
obstruction (Kuhn et al., 2011). In OAB patients, DWT was reduced after anti-muscarinic 
treatment (Liu et al., 2009b; Kuo et al., 2010b). In addition, a positive correlation has been 
found between the presence of OAB and high BWT/DT(Robinson et al., 2002; Kuo, 2009).  
However, the reliability of DT as a marker for DO or OAB is still debatable. BWT/DT are 
typically measured by ultrasound. One particular problematic issue is the well-known 
bias associated to the different operators of ultrasound. Another unsolved issue regards 
the best way to measure BWT/DT. Should the bladder be empty of filled? If filled, at 
which volume? Should one use an abdominal or transvaginal approach? Which are the 
costs? In addition, several studies failed to demonstrate significant differences between 
healthy controls, patients with DO, bladder outlet obstruction or with increased bladder 
sensation (Blatt et al., 2008). More recently, Liu et al measured the DT in normal controls 
and patients suffering from OAB or interstitial cystitis (Liu et al., 2009b). They found a 
wide variation amongst all groups of individuals with a trend of higher BWT/DT in OAB-
wet patients that did not reach statistical significance. In another study, no differences in 
the BWT/DT were found between OAB patients and individuals with no OAB symptoms 
(Chung et al., 2010).  
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Clearly, the measurement of BWT or DT by ultrasound faces some drawbacks that are not 
yet overcome. Intra- and inter-operator variability in ultrasound measurements is probably 
the most important one. The use of different ultrasound probes, as well as in the resolutions 
of ultrasound-generated images (Kuo, 2009), is another limiting factor to the use of 
BWT/DT as a biomarker. Although clinically appealing, more studies are necessary before it 
becomes a tool for daily practice.  
3. Urinary biomarkers 
3.1 Prostaglandins 
Prostanoids (prostaglandins and thromboxanes) are synthesized by cyclo-oxygenase (COX), 
present in several tissues including the bladder wall (Khan et al., 1998; Lecci et al., 2000; 
Azadzoi et al., 2003; Andersson & Wein, 2004). Two COX isoforms exist. COX-1 is expressed 
constitutively and participates in normal bladder function whereas COX-2 is activated 
during cystitis (Lecci et al., 2000; Tramontana et al., 2000). Prostanoid synthesis can be 
induced by physiological stimuli (for example, detrusor muscle stretching), injuries of the 
mucosa, nerve stimulation, ATP and inflammatory mediators such as bradykinin and the 
chemotactic peptide N-formyl-l-methionyl-l-leucyl-l-phenylalanine (Khan et al., 1998; 
Andersson & Wein, 2004). 
Prostaglandin (PG) E2 is one the most abundant prostanoid in the bladder (Jeremy et al., 
1987; Khan et al., 1998). In rats, intravesical administration of PGE2 facilitates micturition, 
increases basal intravesical pressure and induces bladder hyperactivity (Ishizuka et al., 
1995). In the urethra, topical application of PGE2 causes relaxation of the sphincter 
(Yokoyama et al., 2007). Likewise, intravesical instillation of an inhibitor of the COX-2 
enzyme improved bladder function in an animal model of OAB (Jang et al., 2006).  This 
supports a role for this prostanoid during bladder dysfunction and has justified a few 
inconclusive clinical trials regarding the use of non-steroidal anti-inflammatory drugs in the 
treatment of OAB. So, expectations were raised when Kim and co-workers found that levels 
of PGE2 and PGF2┙ were significantly higher in male and female OAB patients that in 
healthy controls (Kim et al., 2005; Kim et al., 2006). However, PG concentrations were not 
corrected for urine concentration. After correction for creatinine values, Liu and co-workers 
found no significant differences in PGE2 content in patients with OAB wet, OAB dry and 
controls (Liu et al., 2010).  
Thus, at this moment the role of urinary PGs, most notably PGE2, as a putative tool for OAB 
diagnosis and follow-up is highly debatable. Moreover, the measuring methods rely on 
labour-intensive and expensive laboratory procedures. In addition, although it is relatively 
consensual that prostanoids participate in the mechanisms of OAB, it is not known if the 
recommended OAB therapies effectively reduce the PGs levels.  
3.2 Urinary cytokines 
The presence of cytokines in the urine has been addressed in various bladder and kidney 
disorders, including chronic renal disease, interstitial cystitis and vesicoureteral reflux 
(Ninan et al., 1999; Abdel-Mageed et al., 2003). It has been suggested that OAB may result 
from an underlying inflammation of the bladder, a hypothesis supported by recent studies 
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reporting the presence of histological signs of inflammation in biopsies from OAB patients 
(Comperat et al., 2006; Apostolidis et al., 2008). However, confirming the presence of 
inflammation through biopsies is certainly an invasive procedure not exempt of morbidities. 
The detection of signs of inflammation in the urine of OAB patients is a more attractive 
alternative. Tyagi and co-workers have recently collected urine samples from patients and 
determined the levels of various cytokines, chemokines, growth factors and soluble 
receptors (Tyagi et al., 2010). Using a luminometry-based assay, they found a significant 
increase, when compared with controls, in the concentration of various elements, including 
the monocyte chemotatic protein-1 (MCP-1), the soluble fraction of the CD40 ligand, the 
macrophage inflammatory protein (MIP-1┚) and interleukins 10, 5 and 12. Another group of 
researchers also analysed of urine samples from healthy individuals and OAB patients using 
a proteomic approach (Ghoniem et al., 2011). Interestingly, their results indicate that while 
the concentration of certain elements increases (such as interleukin 16), the concentration of 
others decreases (such as interleukin 7). Thus, the actual role of all of these cytokines in OAB 
is far from being well understood, undermining its utility as biomarkers.  
3.3 Neurotrophins 
Neurotrophins are tissue-derived trophic factors necessary for the embryonic 
differentiation, survival and maintenance of neuronal cells both in the peripheral and 
central nervous system (Pezet & McMahon, 2006). The most well studied neurotrophins are 
Nerve Growth Factor (NGF) and Brain Derived Neurotrophic Factor (BDNF). They exert 
their effects via their specific tyrosine kinase (Trk) receptors. NGF binds to TrkA while TrkB 
is the receptor of BDNF. Both TrkA and TrkB are present in the bladder urothelium and 
sensory afferents innervating the organ (Qiao & M.A. Vizzard, 2002; Murray et al., 2004).  
3.3.1 Nerve Growth Factor (NGF) 
NGF has attracted considerable attention in the Urology field. It is accepted that NGF is 
produced by detrusor muscle cells and by the urothelium (Steers et al., 1991; Steers et al., 
1996; Clemow et al., 1997; Clemow et al., 2000; Steers & Tuttle, 2006). In humans and in 
rodents, the production of NGF in the lower urinary tract and in the neuronal circuits 
regulating bladder function is increased in pathological conditions, including cystitis and 
spinal cord injury (Lowe et al., 1997; Vizzard, 2000; Murray et al., 2004). In addition, 
exogenous NGF is known to induce bladder overactivity, irrespective of the route of 
delivery (Lamb et al., 2004; Yoshimura et al., 2006; Zvara & Vizzard, 2007). Likewise, 
manipulation of NGF levels improves bladder function and referred pain in rats with 
cystitis (Hu et al., 2005; Frias et al., 2009).    
Recent studies have demonstrated the presence of NGF in the urine of OAB patients (Kim et 
al., 2005; Kim et al., 2006; Liu & Kuo, 2008; Liu et al., 2009a, b; Liu et al., 2009c; Jacobs et al., 
2010; Liu et al., 2011a). Levels were significantly higher than in healthy individuals and 
subsided after successful treatment with antimuscarinics (Liu et al., 2009b) or botulinum 
toxin-A (Liu et al., 2009a), in parallel with a decrease in the USS score. Based on these 
results, some authors have forwarded the use of NGF as presumed biomarker for OAB (Kuo 
et al., 2010a). Nevertheless, caution should be advised as most studies have not been placebo 
controlled which may hamper the interpretation of results.  
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3.3.2 Brain Derived Neurotrophic Factor (BDNF) 
The presence and role of BDNF in the bladder has been scarcely analysed and available 
results mostly refer to rodent models of bladder dysfunction. Like NGF, BDNF can be 
synthesized by bladder cells, most notably the urothelium during cystitis (Pinto et al., 2010a) 
or spinal cord injury (Vizzard, 2000). The expression of TrkB is also abundant in sensory 
neurons innervating the bladder wall (Qiao & Vizzard, 2002; Murray et al., 2004). Like in 
somatic tissue (Kerr et al., 1999; Thompson et al., 1999), BDNF expression in the bladder 
seems to be under the control of NGF (Schnegelsberg et al., 2010; Girard et al., 2011). BDNF 
appears to be a key participant in bladder dysfunction in an animal model of cystitis as its 
sequestration improved both bladder reflex activity and peripheral hypersensitivity (Frias et 
al., 2009; Pinto et al., 2010a).  
In humans, it has been reported that urinary BDNF is elevated in patients suffering from 
bladder pain syndrome/interstitial cystitis (Pinto et al., 2010b). In OAB, a recent study 
demonstrated that urinary BDNF was also elevated and significantly decreased after 
therapeutic intervention (Antunes-Lopes et al., 2011). In addition, the concentration of 
urinary BDNF was shown to be decreased to normal values after successful OAB treatment 
(Antunes-Lopes et al., unpublished observations). This may indicate that, like NGF (Kuo et 
al., 2010a), urinary BDNF may serve as an OAB biomarker. However, further studies are 
necessary to fully understand the importance of BDNF in OAB, particularly how it can 
influence the OAB outcome.  
4. Urinary proteomics 
There is a considerable interest in urine as a source of biomarkers for bladder pathologies, 
OAB assuming one of the foremost active areas of research. Indeed, urine is one of the most 
versatile biofluids as it can be easily obtained in large quantities with non-invasive methods 
and is stable in comparison with other fluids. Several peptides and low molecular weight 
proteins can be found in urine. When urine is collected for analysis, most of them should 
have undergone physiological proteolysis as urine may stagnate for hours in the bladder 
before micturition occurs. This might constitute an advantage as, in contrast with blood, 
serum or plasma, urinary proteins and peptides will not undergo further degradation upon 
collection (Kolch et al., 2005; Omenn et al., 2005).  
With the advent and improvement of proteomic analysis, increasing attention has been 
given to the description of the urinary proteome. The number of proteins identified in the 
human urine is still increasing and is well above 1500 (Adachi et al., 2006; Good et al., 2010). 
The combination of different analysis methods and sample treatment recently allowed the 
identification of more than 100 000 peptides, 5000 of which were present in more than 40% 
of the individuals analysed (Coon et al., 2008). Several methods are currently being used to 
analyse the urinary proteome, including two dimensional gel electrophoresis mass 
spectrometry (2DE-MS), liquid chromatography MS (LC-MS), surface-enhanced laser 
desorption/ionization (SELDI-TOF) and capillary electrophoresis MS (CE-MS). If interested 
in more details and the specific advantages and disadvantages of each method, the readers 
are advised to seek that information elsewhere (Decramer et al., 2008). 
With the recent advances in urinary proteomics,  researchers are becoming more aware of 
problems arising during storage and preparation of samples. One important issue is the 
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stability of urine samples. Studies show that sequential freeze/thaw cycles may affect the 
concentration of certain proteins. Schaub and co-workers showed that there were no 
significant differences in the protein profile between samples analysed before freezing and 
after 1 to 4 freeze-thaw cycles (Schaub et al., 2004). These results have been confirmed in 
subsequent studies by non-related groups (Fiedler et al., 2007; Thongboonkerd, 2007). No 
data is available regarding the proteomic analysis of the urine of OAB patients. 
5. Serum biomarkers 
5.1 C- reactive protein (CRP) 
CRP is a highly conserved plasma protein. It was identified in the 1930’s in the sera of 
patients in the acute phase of pneumonia by Tillet and co-workers (Tillett & Francis, 1930; 
Black et al., 2004). Further studies demonstrated that the concentration of CRP in plasma is 
significantly increased during inflammatory states, a characteristic that has often been used 
for diagnostic purposes. In what concerns the urinary tract, plasma CRP has been used to 
monitor the progression of bladder cancer (Hilmy et al., 2006; Gakis et al., 2011a; Gakis et al., 
2011b). As far as we are aware, CRP has been addressed in OAB only in a recent pilot study. 
Chung and co-workers observed higher levels of serum CRP in OAB patients than in 
controls, particularly in the group of OAB wet patients (Chung et al., 2011). Both urinary 
CRP and the amount of CRP mRNA present in the bladder wall were very low, indicating 
that the serum is the body fluid of choice to measure this protein. However, one should be 
aware that serum CRP would most likely reflect the presence of any inflammatory condition 
(Black et al., 2004), making its use as a putative biomarker in OAB is very modest. 
5.2 Serum NGF 
Like in urine, the presence of NGF in the serum of OAB patients has also been investigated 
(Liu et al., 2011b). The authors found a positive correlation between urinary and serum NGF 
contents. Interestingly, serum NGF remained elevated in OAB patients not responding to 
antimuscarinic treatment, suggesting that increased circulating NGF may be a factor in 
refractory OAB. This is, however, the only available study regarding serum NGF levels in 
OAB. It is presently not clear if the high content of NGF in the serum was strictly associated 
with OAB or dependent on associated comorbidities (hypertension, diabetes, coronary 
arterial disease, etc.) (Brown et al., 2000). More studies are needed in order to fully 
understand the relevance of serum NGF in OAB. 
6. Conclusion 
Clinicians and researchers are still far from having a tool to efficiently detect and monitor 
OAB. Several attempts have been made to identify specific bladder parameters, serum and 
urinary proteins that could fulfil such purpose. In all cases, researchers have come across 
issues. Due to several problems, the real clinical relevance of each proposed biomarker is 
still very much unclear, most of the publications reflecting more the willingness of the 
investigators rather than the true scientific value of findings. More studies are clearly 
necessary. In the near future, it is likely that some of these issues are overcome, as 
researchers are increasingly aware of the need to standardize methodologies and are already 
proposing basic protocols that could be easily adopted by most laboratories. Multicentre 
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collaborative studies are also necessary to increase the size of the cohorts analysed and 
decrease the obvious bias of single centre findings. Hopefully, this area of research will 
arrive to a positive destiny with a beneficial impact on the diagnosis and outcome of OAB 
patients. 
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